WE FUND RESEARCH INTO ANY TYPE OF CANCER, ANYWHERE IN THE WORLD
Every new treatment and cure for cancer starts with this question. And that’s where it stops, unless funding is there to pursue the answer all the way. If you want to help us keep turning ‘what ifs’ into ‘we haves’, here’s another way.
Inspired by the recent Virgin Money London Marathon? Don't delay - join our team today!
Sign up now
Olaparib is the first of a new class of cancer drugs called PARP inhibitors. In December 2015, olaparib was approved for ovarian cancer treatment in the UK, and Worldwide Cancer Research played a part in its development.
Find out more